ClinicalTrials.gg
Not yet recruitingNCT06774664Updated Jan 14, 2025

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

A Phase 1/2 interventional study of SCTC21C in IgA Nephropathy, sponsored by Sinocelltech Ltd.. Not yet recruiting at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
48th of 109
99 · median 84
Started
2025
with 19 others
Phase 1/2
2 of 127
2 open now
Primary completion
2027-09
later than 37 of 72 live
Registered
79th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 48th largest by planned enrollment of the 109 interventional ones that give a count, is one of 20 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 37 of the 72 other live ones, and was the 79th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 69 Glomerulonephritis, IGA studies recruiting now, 40 (58%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases

Read the detailed description

This is a randomized, double-blind, placebo-controlled Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of SCTC21C in subjects with plasma cell-driven autoimmune diseases.

In phase 1 study, participants will be assigned to receive sequentially higher doses of SCTC21C to determine the recommended dose of SCTC21C for the randomized dose optimization- stage. In phase 2 study, 2 dose levels will be used. A total of 72 participants will be randomized in a 1:1:1 ration to dose 1, dose 2 or placebo groups to better understand the exposure/efficacy/toxicity relationship.

03

Conditions studied

  • IgA Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years at the time of signing the ICF;
  2. The subject has been diagnosed with IgA nephropathy through kidney tissue ;
  3. The subject has been on a stable and maximally tolerated dose of ACEI or ARB (or the maximum allowable dose according to the prescribing information) for at least 12 weeks prior to the first dose. Subjects using both ACEI and ARB simultaneously will not be accepted;
  4. The estimated (eGFR) calculated using the CKD-EPI formula must be ≥30 mL/min/1.73 m²;
  5. During the screening period, the subject must have 24-hour proteinuria ≥1.0 g or a urine protein-to-creatinine ratio (UPCR) ≥0.75 g/g based on 24-hour urine protein;
  6. All male subjects or women of (with a negative blood pregnancy test within 7 days prior to the first dose of drug) must agree to use reliable together with their partner from the time of signing the ICF until 5 months after the last dose of the study drug;
  7. Understand the study procedures and voluntarily sign the form in writing.

Exclusion criteria

Exclusion Criteria:

  1. IgA nephropathy secondary to other diseases;
  2. Any kidney disease with special pathological or clinical types, such as nephrotic syndrome, crescentic glomerulonephritis, etc.;
  3. Use of systemic within the 3 months prior to baseline or expected use during the study period;
  4. Use of systemic drugs within the 3 months prior to baseline or expected use during the study period;
  5. Use of other B-cell-targeting biologics or unapproved biologics within the 6 months prior to baseline;
  6. Patients who have experienced any of the following cardiovascular events within 24 weeks prior to baseline: myocardial infarction, unstable angina, ventricular arrhythmias, heart failure with class II or higher, stroke, etc.;
  7. A history of solid organ or hematopoietic stem cell or bone marrow transplantation, or expected to undergo a transplant procedure during the treatment period with the investigational drug;
  8. Currently undergoing hemodialysis or peritoneal dialysis, or expected to require hemodialysis or peritoneal dialysis during the treatment period with the investigational drug;
  9. Any symptoms or signs within 30 days prior to baseline indicating an active infection (excluding the common cold), or requiring systemic anti-infective treatment, or being at high risk for infection;
  10. Positive viral serology, including , , and , etc.; Hepatitis B patients: active hepatitis or severe liver disease;
  11. Currently or within the past 5 years has had malignant tumors, except for fully treated skin basal cell carcinoma, squamous cell carcinoma, cervical carcinoma in situ, or cervical intraepithelial neoplasia;
  12. Known allergy to the active ingredient or of the investigational drug.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    Phase I: Dose-finding: Group 1

    Drug: SCTC21C Administered SC

    Biological: SCTC21C

  • Experimental
    Phase I: Dose-finding: Group 2

    Drug: SCTC21C Administered SC

    Biological: SCTC21C

  • Experimental
    Phase I: Dose-finding: Group 3

    Drug: SCTC21C Administered SC

    Biological: SCTC21C

  • Experimental
    Phase I: Dose-finding: Group 4

    Drug: SCTC21C Administered SC

    Biological: SCTC21C

  • Experimental
    Phase 2: Group 1

    Drug: SCTC21C Administered SC

    Biological: SCTC21C

  • Experimental
    Phase 2: Group 2

    Drug: SCTC21C Administered SC

    Biological: SCTC21C

  • Placebo comparator
    Phase I: Dose-finding: Group 5

    Drug: SCTC21C Administered SC

    Biological: SCTC21C

  • Placebo comparator
    Phase I: Dose-finding: Group 6

    Drug: SCTC21C Administered SC

    Biological: SCTC21C

  • Placebo comparator
    Phase 1: Dose-finding: Group 7

    Drug: SCTC21C Administered SC

    Biological: SCTC21C

  • Placebo comparator
    Phase 2: Group 3

    Drug: SCTC21C Administered SC

    Biological: SCTC21C

Interventions

  • BiologicalSCTC21C

    Drug: SCTC21C Administered SC

06

What researchers measure

Primary outcomes

  1. Phase 1: Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs).

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: Results in death Is life-threatening Requires in patient hospitalisation or prolongation of existing hospitalisation Is a congenital anomaly or birth defect Is an infection that requires treatment parenteral antibiotics Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above.

    Time frame: 36 Weeks

  2. Phase 2: Percentage change in urine protein-to-creatinine ratio (UPCR) at Week 24 compared to baseline

    UPCR is calculated by dividing the concentration of protein in urine by the urine creatinine concentration.

    Time frame: 24 Weeks

Secondary outcomes

  1. Phase 1: Percentage change in urine protein-to-creatinine ratio (UPCR) compared to baseline

    UPCR is calculated by dividing the concentration of protein in urine by the urine creatinine concentration.

    Time frame: 36 Weeks

  2. Phase 1: Percentage change in 24-hour urinary protein excretion compared to baseline

    Time frame: 36 Weeks

  3. Phase 1: Percentage change in urine albumin-to-creatinine ratio (UACR) compared to baseline

    UACR is calculated by dividing the concentration of albumin in urine by the urine creatinine concentration.

    Time frame: 36 Weeks

  4. Phase 1: Percentage change in eGFR compared to baseline

    eGFR is calculated using the CKD-EPI formula.

    Time frame: 36 Weeks

  5. Phase 1: Change from baseline in Immunoglobulin A (IgA), Immunoglobulin M (IgM), Immunoglobulin G (IgG), etc.

    Time frame: 36 Weeks

  6. Phase 1: C-max

    Maximum observed plasma concentration

    Time frame: 24 Weeks

  7. Phase 1: T1/2

    apparent terminal half-life

    Time frame: 24 Weeks

  8. Phase 1: AUC0-t

    area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration

    Time frame: 24 Weeks

  9. Phase 1: Percentage of Participants With Positive Antidrug Antibody (ADA) and Neutralizing Antibody (Nab)

    Results for ADA analysis were reported.

    Time frame: 36 Weeks

  10. Phase 2: Percentage change in urine protein-to-creatinine ratio (UPCR) compared to baseline

    UPCR is calculated by dividing the concentration of protein in urine by the urine creatinine concentration.

    Time frame: 104 Weeks

  11. Phase 2: Percentage change in 24-hour urinary protein excretion compared to baseline

    Time frame: 104 Weeks

  12. Phase 2: Percentage change in urine albumin-to-creatinine ratio (UACR) excretion compared to baseline

    UPCR is calculated by dividing the concentration of albumin in urine by the urine creatinine concentration.

    Time frame: 104 Weeks

  13. Phase 2: Percentage change in eGFR compared to baseline

    eGFR is calculated using the CKD-EPI formula.

    Time frame: 104 Weeks

  14. Phase 2: Change from baseline in Immunoglobulin A (IgA), Immunoglobulin M (IgM), Immunoglobulin G (IgG), etc.

    Time frame: 104 Weeks

  15. Phase 2: C-max

    Maximum observed plasma concentration

    Time frame: 32 Weeks

  16. Phase 2: T1/2

    apparent terminal half-life

    Time frame: 32 Weeks

  17. Phase 2: AUC0-t

    area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration

    Time frame: 32 Weeks

  18. Phase 2: Percentage of Participants With Positive Antidrug Antibody (ADA) and Neutralizing Antibody (Nab)

    Results for ADA analysis were reported.

    Time frame: 104 Weeks

07

Study locations

20 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Sep 2027, 32 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 14, 2025
StartEst.
Jan 2025
Primary completionEst.
Sep 2027
CompletionEst.
Mar 2029
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06774664
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Jan 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jan 14, 2025

Study contacts

Qiang Zhou
Contact
qiang_zhou@sinocelltech.com
+86-10-58628288
Hong Zhang
principal investigator · Peking University First Hospital, Department of Nephrology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD38 Monoclonal Antibody SCTC21C

Start the discussion